stockportfolio.pro
Stocks / EBS vs KMDA
EBS vs KMDA
Emergent BioSolutions Inc. and Kamada Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Emergent BioSolutions Inc. (EBS) | Kamada Ltd. (KMDA) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $705.20M | $180.46M |
| Net income (latest FY) | $52.60M | $20.20M |
| Revenue growth (5y CAGR) | -14.9% | 11.7% |
| Net margin | 7.5% | 11.2% |
| Return on equity | 10.1% | 7.5% |
| P/E ratio | — | 20.9 |
| Dividend yield | — | 3.5% |
| Profitable years (of last 10) | 7 | 3 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EBS — free Open KMDA — freeFrequently asked questions
Which is bigger, EBS or KMDA?
Emergent BioSolutions Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, EBS or KMDA?
Over the last five fiscal years, Kamada Ltd. grew revenue faster — 11.7%/yr versus -14.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.